All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CB5138 Analog peptides,Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Preclinical data shows that combination of a CB5138 Analog with nintedanib, the leading standard of care for treatment of Idiopathic Pulmonary Fibrosis (IPF), produced enhanced effects compared to nintedanib alone in mice.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant human plasma gelsolin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
The compelling data from this NIH sponsored study show the potential of gelsolin to not only improve survival, but to diminish lung injury caused by virulent pneumonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Exebacase
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CF-370
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 25, 2020
Details:
First stage of the agreement will fund in vitro activity of ContraFect’s next product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa, and amurin peptides, against bacterial specimens obtained from CF patients at different stages of disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MORF-720
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MORF-720
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $120.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement August 25, 2020
Details:
AbbVie has exercised a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASX-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Orange Grove Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 25, 2020
Details:
ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials of the drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Larazotide Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INN-202
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent for Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MRG-229
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MRG-229
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
MRG-229 has demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sinapultide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co
Deal Size: $20.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 22, 2020
Details:
Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinical development of AEROSURF;pre-clinical studies of SERCA2a activators.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MBT2
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020
Details:
CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MBT2
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Details:
The presentation highlights potential of MBT2 to Inhibit Fibrogenesis in Cultured Human Lung Cells and its efficacy in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
